The company manufactures and prints specialized knitted fabrics used primarily for mattresses and home furnishings, serving major B2B clients like Sleepwell and Kurlon.
While the company claims specialized customization for major brands, the low net margin of 5.5% and the sharp decline in EPS despite revenue growth suggest a lack of durable pricing power or cost advantage. The business operates in a competitive textile segment where customization does not translate into high returns on capital.
Management utilized IPO proceeds for working capital and debt repayment, but the massive divergence between revenue growth and EPS contraction indicates that reinvested capital is not currently yielding profitable growth for shareholders.
The investment collapsed as the massive divergence between top-line growth and bottom-line profitability became a permanent feature of the business. Management continued to chase low-margin revenue while internal costs and related-party leakages ballooned, leading to further EPS erosion. The poor cash conversion eventually starved the company of liquidity, and the lack of pricing power meant they were merely a high-volume, low-profit pass-through for larger brands. The market finally re-rated the stock from a growth story to a commodity textile processor as the promoter-centric governance failed to protect minority interests.
RichFakir rates Rachit Prints Ltd's business quality as mediocre — 45/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Rachit Prints Ltd is trading about 63% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Rachit Prints Ltd is: Not rated. A mediocre business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Rachit Prints Ltd's fair value is about ₹98 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →